翰宇药业:HY3003注射液获临床试验申请受理通知书

智通财经
Sep 10
【翰宇药业:HY3003注射液获临床试验申请受理通知书】翰宇药业公告,公司与深圳碳云智肽药物科技有限公司合作开发HY3003注射液,拟用于减重适应症。公司近日收到国家药品监督管理局核准签发的临床试验申请《受理通知书》,受理号为CXHL2601095、CXHL2601096、CXHL2601097、CXHL2601098、CXHL2601099、CXHL2601100。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10